Product Reports Resources Pricing Login Book a demo

OrganOx

Health Tech & Medtech · Oxford, United Kingdom · Founded 2008

Normothermic organ perfusion system for liver transplantation MoreLess

OrganOx is a commercial-stage medical technology company that spun out of the University of Oxford in April 2008. It was founded by Professor Peter Friend, a transplant surgeon, and Professor Constantin Coussios, a biomedical engineer, who collaborated to address the shortage of viable organs for transplantation. Their combined expertise in surgery and biomedical engineering led to the development of the company's core technology over more than 15 years.

The company's flagship product is the OrganOx metra®, a portable, automated device for normothermic machine perfusion (NMP) of donor livers. Unlike conventional cold storage at 4°C, the metra® system maintains the liver at a normal body temperature of 37°C, continuously perfusing it with oxygenated blood, nutrients, and medications. This process mimics the organ's physiological environment, keeping it functional and allowing for objective assessment of its health and viability prior to transplantation. The ability to preserve organs for up to 24 hours significantly extends the window for transplantation, improves logistics, and has been shown to reduce the number of discarded organs.

OrganOx operates on a business model that involves leasing its metra® devices to transplant centers and hospitals, supplemented by the sale of single-use disposable perfusion sets required for each procedure. Its clients are specialist liver transplant units in markets including Europe, the U.S., Canada, and Australia. The company has raised significant funding, including a $160 million financing round in 2025, to expand its commercial footprint, build new manufacturing facilities, and fund further clinical evaluations. OrganOx is also developing its technology for other applications, including kidney transplantation and in combination with genetically engineered porcine livers to support patients with acute-on-chronic liver failure.

Keywords: normothermic machine perfusion, organ preservation, liver transplantation, organ perfusion systems, ex vivo organ assessment, medical device, transplant logistics, transplant surgery, organ viability, donor organ, medtech, biomedical engineering, isolated organ perfusion, allograft dysfunction, organ failure treatment, surgical devices, healthcare technology, clinical trials, FDA approved medical device, CE marked device

Valuation $1–2.5B
Revenue $50–100M
Headcount 100–500
Total funding $50–100M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for OrganOx and the history behind them.

Talent graph

OrganOx's talent

Book a demo to see the people
Employees mapped 242 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 9 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

15 investors on OrganOx's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 4 investors entered at this stage
Oxford Technology
Adam Niewinski
Technikos
Royal Society Enterprise Fund
Series B+ 11 investors entered at this stage
Business Growth Fund
Lauxera Capital Partners
HealthQuest Capital
Terumo
Intuitive Ventures
Longwall Ventures
Avidity Partners
Soleus Capital
University of Oxford
Sofina
Piper Heartland Healthcare Capital

Global footprint

Where OrganOx has talent and traffic

Workforce by country
5 countries with
team presence
🇬🇧 United Kingdom52.7%
🇺🇸 United States44.7%
🇩🇪 Germany1.1%
🇫🇷 France1.1%
🇨🇭 Switzerland0.5%
5 countries shown
Web traffic by country
9.8K monthly visits
across markets
🇺🇸 United States54.1%
🇬🇧 United Kingdom42.9%
🇮🇳 India4.1%
Top 3 markets shown

Market sentiment

What the market is saying about OrganOx

An AI-synthesized read of the highest-engagement posts about OrganOx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OrganOx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.